NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

NCT05661201 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor
KRAS Mutation-Related Tumors

Interventions

DRUG: NEROFE
DRUG: Doxorubicin

Sponsor

Georgetown University

Collaborators

[object Object]